Key result
Prescription icosapent ethyl cuts MACE ~25% vs placebo, whereas omega-3 supplements lack proven CV benefit.
Why the study?
Available omega-3 fatty acid products in the US are either nonprescription dietary supplements or prescription medications, prompting a need to describe critical therapeutic differences between them.
Hazard Ratio: 0.75 (95% CI 0.68–0.83)
Absolute Event Rate: 17.2% vs 22%
Absolute Risk Reduction: 4.8%
Number Needed to Treat: 21
p-value: p=<0.001
Healthcare providers and consumers should not substitute dietary omega-3 supplements for prescription omega-3 products due to critical differences in regulation, purity, and proven clinical efficacy.
Rx OM-3s differ therapeutically from supplements; leaves open whether distinctions affect clinical outcomes.
INTRODUCTION: Currently available omega-3 (OM-3) fatty acid products in the US are either nonprescription dietary supplements (e.g., fish oils) or prescription (Rx) medications. As such, we aimed to describe critical therapeutic differences among the OM-3 fatty acids, focusing on differences between fish oil supplements and Rx OM-3s. METHODS: A narrative review of known papers salient to this topic was conducted. RESULTS: Despite the multiple purported clinical benefits, the published evidence for OM-3 dietary supplements is generally insufficient, inconsistent, or negative. Rx OM-3 products are indicated as an adjunct to diet to reduce triglycerides (TG) in adults with severe hypertriglyceridemia (TG ≥ 500 mg/dl). Recently, the Rx eicosapentaenoic acid (EPA)-only OM-3, icosapent ethyl, demonstrated cardiovascular (CV) risk reduction among statin-treated patients at high risk of CV disease in a large CV outcomes trial (CVOT), and is now also indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated TG (≥ 150 mg/dL) and established CVD or diabetes mellitus and ≥ 2 additional risk factors for CVD. In contrast to the rigorous regulatory standards for safety, efficacy, and manufacturing of medications (whether Rx or over the counter), the Food and Drug Administration manages dietary supplements as food. Issues specific to OM-3 dietary supplements include variable content, labeling inconsistencies, and poor product quality/impurity. Given these issues, OM-3 dietary supplements should not be substituted for Rx OM-3 products. The efficacy of the EPA-only Rx OM-3 product in a large CVOT cannot be extrapolated to other OM-3 products. CONCLUSION: Consumers and health care providers need to recognize critical differences between Rx and OM-3 dietary supplements to ensure appropriate use of each OM-3 product.
No takes yet. Share an insight, caveat, or question.
Hilleman et al. (2020) conducted a review in Cardiovascular disease and hypertriglyceridemia. Prescription omega-3 fatty acids (icosapent ethyl) vs. Placebo / Omega-3 dietary supplements was evaluated on Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina (REDUCE-IT trial data) (HR 0.75, 95% CI 0.68-0.83, p=<0.001). Prescription icosapent ethyl significantly reduced major cardiovascular events by 25% (HR 0.75) compared to placebo, whereas omega-3 dietary supplements lack proven cardiovascular benefits and regulatory oversight.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: